Category Archives: Advocacy

A Hep C Advocate’s 2014

Luster-Daryl-2015As we have just rung in 2015, the Hepatitis C Treatment Information Project wanted to look back and highlight some of the 2014 work of one of our hep C advocates.

The following is a collection of 2014 articles and resources that Daryl Luster, hep C advocate and president of PHCN,  was a part of:

January 13  –  CADTH Letter  (Canadian Agency for Drugs and Technologies in Health)

February 19  –  Daryl Luster and the work of Pacific Hep C Network  (PHCN)

May 30  –  Highly effective new drugs for hepatitis C jostle for market share: No provincial health system covers the medications, but lobbying is already underway to make sure they do  (Vancouver Sun)

July 17  –  Vancouver Resident Raises Awareness for World Hepatitis Day  (Hello Vancity)

July 21  –  Note to Editor: World Hepatitis Day is a time to rethink the future impact of untreated Hepatitis C in Alberta  (iStockAnalyst.com)

July 25  –  Richmondite Spreads Hep C Awareness  (Richmond News)

August 1  –  Hep Stories: Daryl Luster  (hepmag.com)

October 1  –  Hepc.bull Mention and Pictures on Page 5  (hepc.bull)

October 8  –  ‘If you have money, you’ll live. If you don’t, you’ll die’: B.C.’s Hepatitis C sufferers hope for fast drug approval  (The Province)

November 5 – 6  –  Virology Education  (1st International Hepatitis Cure & Eradication Meeting)

November 13  –  Bristol-Myers Squibb Announces High Cure Rates for Genotype 3 Hepatitis C Using Combination of Daclatasvir and Sofosbuvir in ALLY-3 Trial  (Bristol-Myers Squibb)

November 25  –  Richmond Centre for Disability Empower Series  (Richmond Centre for Disability)

December  –  Hepc.bull Mention and Pictures on Page 4  (hepc.bull)

We also wanted to wish you all a happy new year! May the coming year bring new treatments, medical breakthroughs, and hope.

An honour

sq_trialsThank you to all of you who completed PHCN’s Ombitasvir / Paritaprevir / Ritonavir and Dasabuvir survey and shared it with others. It was truly an honour to read your responses and to use them to write the patient group input report for the Canadian Agency for Drugs and Technologies in Health (CADTH) on your behalf.

The patient group input reports requested by CADTH are an important step towards getting new treatments for hep C more widely available in Canada and BC.

You can find a slightly shortened version of the report on PHCN’s Resources page.

The report was sent in this morning. We now wait to hear the outcome of the treatment’s submission. The Hepatitis C Treatment Information Project will keep you apprised of any news.

PHCN’s Hepatitis C Treatment Information Project is a source of information that doesn’t post a ‘site last modified date’ because it is truly forever changing. Pay it a visit for more information about currently approved hep C treatments in BC, new and emerging drugs, the drug approval process in Canada and BC, resources to help in getting ready for treatment, or just to try to figure out what pages have been newly added in the last week or two! You can also email us your questions about hep C treatments.

Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.

MLA’s luncheon

sq_experiencesOn November 18th, the PHCN hosted Honourable Terry Lake, BC Minister of Health, and 15 other BC Government MLAs at a MLA’s luncheon in Victoria. Speeches were made about hepatitis C and the policy changes needed to ensure that more people in BC get tested, treated, and cured of hepatitis C.

Daryl Luster, PHCN Board President, described his experience with hepatitis C—beginning to feel ill, 3 years of tests and worsening symptoms, an ‘accidental’ hepatitis C diagnosis, and a fortunate clinical trial where Daryl, after a fairly debilitating round of new and old hep C treatments, cleared the virus. Daryl spoke of how he wanted to spare other hep C patients the experience of worsening symptoms and not being able to find help for far too long. He made a promise then to work hard to see changes that would make it easier for anyone with hepatitis C to get tested, treated, and cured.

Dr. Mel Krajden, Director of BC Hepatitis Services at the BC Centre for Disease Control (BCCDC), presented as well. Dr. Krajden spoke to the different groups of people with hep C—baby boomers, people who use injection drugs, immigrant populations, and aboriginal communities—and about how each group has specific needs. He said that while the Treatment as Prevention is a good approach for reaching and engaging people who are marginalized, other strategies are required. For instance, for baby boomers, he recommends a ‘Test, Triage, and Treat’ approach.

We spoke to the need for new treatments to be listed with PharmaCare with no unnecessary restrictions as soon as possible. We urged the government to seize the opportunity to be leaders in the fight to eradicate hepatitis C—a very real possibility.

Health Minister Lake spoke to the government’s commitment to addressing viral hepatitis and the ongoing negotiations with pharmaceutical companies for new drug prices. The Ministry of Health sees great value in the ‘Treatment as Prevention’ approach.

We hope that the government also sees that different populations have different needs and we want to be smart and strategic in how needs are met!

In addition, Daryl and Dr. Mel Krajden also met with political staff in Minister Lake’s office as well as with Ministry of Health staff in the Population and Public Health branch to discuss these same issues.

Stay tuned for more Hep C TIP Advocacy News!

Take this Survey

ombitasvir / paritaprevir / ritonavir and dasabuvir (HOLKIRA PAK) Survey Logo

Take this survey.

Survey participants with hep C or living with/caring for someone with hep C wholesale mlb jerseys needed immediately!

The LEDIPASVIR/SOFOSBUVIR Canadian Agency for Drugs and Technologies in Health (CADTH) is currently seeking patient group input reports for ombitasvir / paritaprevir Copyright / ritonavir and dasabuvir (HOLKIRA PAK), developed by AbbVie. Thus, Pacific Hepatitis C Network (PHCN) needs your help for our report.

The patient group input reports requested by CADTH are an important step towards getting new treatments for hep C more widely available in Canada and BC. You can be a part of this process!

The survey is newly la redesigned and includes 33 questions, mostly multiple choice, that are divided into five sections. cheap jerseys The sections that don’t needed pertain to you, such as the section about your experience with ombitasvir / paritaprevir / ritonavir and dasabuvir (HOLKIRA PAK) if you’ve never taken this hep C treatment, can be easily skipped. Those living with/caring for Managing someone with hep Simeprevir C are only asked to complete eight questions.

Survey responses are anonymous (we wholesale jerseys don’t for know your name or Истребитель other information about you). The information gathered will be used as part of a patient group input report for CADTH. By completing the survey you accept that PHCN can лиц use the information gathered by it in our patient group input report for CADTH.

Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.

Please email hepctip@pacifichepc.org for more information about the survey or visit PHCN’s Hepatitis C Treatment Information Project for more information about ombitasvir / paritaprevir / ritonavir and dasabuvir (HOLKIRA PAK) and the different hep C treatments within the drug pipeline.

THANK YOU LEDIPASVIR/SOFOSBUVIR SURVEY TAKERS!

sq_homePacific Hepatitis C Network (PHCN) would like to thank all of those who completed our ledipasvir/sofosbuvir (Harvoni) survey.

The survey was completed wholesale jerseys by dünya! more members than pastor expected and the opinions and experiences that were shared were not just invaluable while writing the patient group input report for the Canadian Agency for Drugs and Technologies in Health (CADTH), but will also be invaluable while creating future surveys.

Yes, there will be future surveys and future blog posts similar to the last post, requesting survey takers, and this post, thanking survey takers. Our task is not done! New hep C treatments are currently making their way through the wholesale jerseys China drug pipeline and we have to be a part of this process!

As we use your comments and suggestions to tweak the ledipasvir/sofosbuvir participants (Harvoni) survey for possible future use, we wait in great anticipation for the next time patient input is cheap jerseys requested by CADTH. Please join us in this anticipation and keep a look out for future requests for survey participants as new treatments are coming and CADTH will again need to hear about our experiences with hep C and our opinions about treatments.

For more information about currently approved hep C фундамент treatments in BC, new and emerging drugs, the drug approval process in Canada and BC, or resources to help wholesale mlb jerseys in getting ready for gegen treatment, please visit PHCN’s Hepatitis C Treatment Information Project or email hepctip@pacifichepc.org.